Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Releases FY 2024 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 5.610-6.045 for the period. The company issued revenue guidance of $51.7 billion-$53.9 billion.

Bayer Aktiengesellschaft Trading Down 3.9 %

Bayer Aktiengesellschaft stock traded down $0.22 during mid-day trading on Thursday, reaching $5.36. 3,506,472 shares of the company traded hands, compared to its average volume of 1,362,203. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.27 and a quick ratio of 0.86. Bayer Aktiengesellschaft has a 52-week low of $5.33 and a 52-week high of $11.33. The firm’s 50 day moving average price is $7.39 and its 200 day moving average price is $7.42. The firm has a market capitalization of $21.06 billion, a price-to-earnings ratio of -20.62 and a beta of 1.10.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.10). Bayer Aktiengesellschaft had a positive return on equity of 16.46% and a negative net margin of 2.02%. The company had revenue of $10.96 billion during the quarter. On average, analysts anticipate that Bayer Aktiengesellschaft will post 1.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Bank of America raised shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a report on Friday, September 6th. One analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.